Kilpatrick Townsend’s Silicon Valley-based start-up team advised the founders of Editas Medicine in the biotech start-up’s $43 million Series A Financing. In a trend setting transaction, venture firms Polaris Partners, Third Rock Ventures, Flagship Ventures and the Partners Innovation Fund invited five of the most prominent research scientists in the field of genomics from MIT, Harvard, the Howard Hughes Medical Institute and the University of California in Berkeley to form a company which they would fund. The money invested will fund the collaborative research and development by this world-class team of scientists as they seek to revolutionize the treatment of genetic disorders by developing a simple, precise and inexpensive method of ‘editing out’ abnormalities in genes in human cells.

Experience Center

Match our Experience to Your Needs

View All Case Studies

Experience Highlights

Successful settlement of UST release-related claims against major oil company
Represented a major oil company in resolving threatened litigation arising from a UST release. Case was settled without litigation for less than 20 more
Merger of Emageon Inc. with AMICAS Inc.
Represented Emageon Inc., a publicly traded medical image software developer, in connection with its merger with AMICAS Inc., a radiology information more
Bankruptcy case for one of the largest bank holding companies located in Georgia
Assisted one of the largest bank holding companies located in Georgia as the secured party lender in recovery of multiple properties that served as more
Benefits counseling services for a non-profit health organization
Assisted a nationwide community-based health organization with the review and updating of their broad-based qualified plans and executive benefit more